BRCA2 and cancer: Although some experiments raise the possibility that BRCA1-deficient cells may be resistant to anti-cancer agents targeting the microtubules (such as vinca alkaloids and taxanes), no preclinical in vivo studies have ever demonstrated taxane resistance in BRCA2-deficient cells (Foulkes, 2006; Robson, 2007b).